Best-in-class absorbable synthetic gel for use as an adjunct in lumbar spine surgery to reduce leg pain and neurological symptoms, now available in the United States.
SAN LUIS OBISPO, California, Nov. 5, 2025 /PRNewswire/ — Fziomed, Inc. (“Fziomed” or the “Company”), a recognized global leader in post-surgical adhesion prevention with a best-in-class synthetic absorbable gel technology platform, today announced that the Company has initiated commercialization of Oxiplex® gel in the United States, indicated to reduce postoperative leg pain and neurological symptoms in adult patients undergoing lumbar spine procedures. Oxiplex is the first and only FDA-cleared intraoperative gel designed specifically for this indication.
“We are proud to introduce Oxiplex to the United States, marking an important step in expanding patient access to our proven dual-polymer technology,” said Ryan Bledsoe, vice president of marketing and market access at Fziomed. “This milestone reflects our unwavering commitment to supporting surgeons with innovative solutions that improve patient outcomes and advance surgical care.”
“Having Oxiplex available in the U.S. provides spine surgeons with a new evidence-based tool to address an important unmet clinical need,” said Alfred L. Rhyne, MD, an orthopedic surgeon specializing in the diagnosis and treatment of spine conditions at OrthoCarolina (Charlotte, North Carolina). “Patients will now benefit from a technology that has been validated in rigorous clinical studies and successfully used in hundreds of thousands of procedures around the world.”
Fziomed’s Oxiplex is a clear, absorbable, safe and easy-to-use gel that is applied directly to the nerves and surrounding tissues during surgery immediately before closure. In spine surgery, Oxiplex acts as a temporary physical barrier between adjacent tissues and has been shown in multiple peer-reviewed publications to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has been available outside the United States since 2002 and has been used in more than 750,000 spine procedures worldwide for the prevention of postoperative adhesions.
Fziomed will attend the 40th Annual Meeting of the North American Spine Society (NASS) on November 14-16, 2025 in Denver, Colorado, and will showcase its Oxiplex absorbable gel for spine surgery. Visit Fziomed at booth #615 during NASS to learn more.
About Fziomed, Inc.
A pioneer in biomaterials since 1996, Fziomed is a recognized global leader in post-surgical adhesion prevention focused on addressing an unmet clinical need in spinal, tendon, nerve, abdominal, pelvic and intrauterine procedures. Fziomed develops, manufactures and markets the best surgical biomaterials used by doctors to preserve surgical excellence and improve patient outcomes.
Fziomed is based in San Luis Obispo, California, and has been named one of the best places to work in Southern California for the past three years in a row.
Visit fziomed.com to learn more about Fziomed and our industry-leading products.
SOURCE Fziomed, Inc.
